1021730-45-9

Upstream product

• 1021733-25-4 4-(2,2-dimethylpropyl)-2-{2-[4-(5-fluoropyridin-2-yl)phenyl]-1-hydroxy-1-methylethyl}-N,N-dimethyl-1H-imidazole-1-sulfonamide 
• 42252-93-7 5-(2,2-dimethylpropyl)-1H-imidazole 
• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 2987-16-8 3,3-dimethylbutyrylaldehyde 
• 1021732-05-7 4-(2,2-dimethylpropyl)-N,N-dimethyl-1H-imidazole-1-sulfonamide 
• 1021733-22-1 4-(2,2-dimethylbutyl)-2-{[4-(5-fluoropyridin-2-yl)phenyl]acetyl}-N,N-dimethyl-1H-imidazole-1-sulfonamide 
• 1021732-53-5 2-[(4-bromophenyl)acetyl]-4-(2,2-dimethylpropyl)-N,N-dimethyl-1H-imidazole-1-sulfonamide 

Relevant academic research and scientific papers

Discovery of MK-5046, a potent, selective bombesin receptor subtype-3 agonist for the treatment of obesity

We report the development and characterization of compound 22 (MK-5046), a potent, selective small molecule agonist of BRS-3 (bombesin receptor subtype-3). In pharmacological testing using diet-induced obese mice, compound 22 caused mechanism-based, dose-

SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS

Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.